Table 2. Clinical and pathological characteristics of the patients with and without IM-SLN imaging.
| Characteristic | Patients of IM-SLN visualized (n = 42) | Patients of IM-SLN not visualized (n = 32) | P value |
|---|---|---|---|
| Subgroup | 0.864 | ||
| cN0→ycN0 | 4 | 4 | |
| cN+→ycN0 | 27 | 21 | |
| cN+→ycN+ | 11 | 7 | |
| Clinical tumor size before NAC (cm) | 0.004 | ||
| ≤ 2 | 7 | 3 | |
| > 2 and ≤ 5 | 30 | 14 | |
| >5 | 5 | 15 | |
| Clinical node stage before NAC | 0.677 | ||
| cN0 | 4 | 4 | |
| cN1 | 18 | 16 | |
| cN2-3 | 20 | 12 | |
| Tumor Location | 0.112 | ||
| Outer | 31 | 16 | |
| Inner | 4 | 7 | |
| Center | 7 | 9 | |
| Pathological node stage | 0.518 | ||
| ypN0 | 13 | 13 | |
| ypN1 | 12 | 10 | |
| ypN2-3 | 17 | 9 | |
| BMI | 0.260 | ||
| 18.5~24.99 | 21 | 20 | |
| 25~28 | 11 | 9 | |
| > 28 | 10 | 3 |
Abbreviations: NAC neoadjuvant chemotherapy; BMI body-mass-index.